Announcement on Preliminary Earnings Estimate for 2025
Filed with SSE · · 3 pages · Chinese
Mabwell (Shanghai) Bioscience Co., Ltd. on 6ix
Earlier from Mabwell (Shanghai) Bioscience
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Earnings Preannouncement for 2025
- Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
- Announcement on Continuing to Use Some Temporarily Idle Raised Funds for Cash Management
Later from Mabwell (Shanghai) Bioscience
- Announcement on the Results of Issuance of the 2026 Phase I Targeted Science and Technology Innovation Bonds
- 2025 Annual Report
- Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors
- SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
- Announcement on Voluntary Disclosure of Acceptance Supplementary Application for Increasing the Indications of Denosumab Injection (MAIWEIJIAN)
Follow Mabwell (Shanghai) Bioscience into a list and get an email when it puts out news.
Follow Mabwell (Shanghai) Bioscience